Novartis, Vanda deal

Vanda regained exclusive U.S. and Canadian rights from Novartis to Fanapt iloperidone. The deal settled a licensing dispute

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE